Transplacental passage of @entity2812 in a XXXX placental perfusion system in vitro and in maternal and cord blood in vivo.

@entity1 @entity71376 @entity302 @entity2812 @entity4591
OBJECTIVE: We studied transplacental passage of @entity2812 ( @entity71376 ; LTG) using an ex vivo @entity1 placental perfusion method and in in vivo samples. METHODS: Term placentas from healthy mothers without medications were perfused in a recirculating dual perfusion system. LTG (2.5 microg/ml, n=4; 10 microg/ml, n=4) and reference compound @entity4591 (100 microg/ml) were added into the maternal circulation. The disappearance of drugs from the maternal circulation and appearance into the foetal circulation was followed every 15 min up to 2 h. Drug concentrations were analysed using high-performance liquid chromatography. In addition to @entity1 placental perfusions, we analysed LTG concentrations in maternal vein and cord blood samples after delivery from two @entity302 mothers receiving LTG therapy during pregnancy. RESULTS: LTG was detectable in the foetal circulation at 15 min in all of the perfusions, indicating rapid transfer. Maternal and foetal concentrations reached equilibrium at 60 min with both concentrations used. The feto-maternal ratio was 1.26+/-0.20 with 10 microg/ml LTG and 0.83+/-0.41 with 2.5 microg/ml LTG at the end of the perfusion. The transfer of LTG from the maternal to the foetal compartment at 120 min was 28.9+/-10.7% with 2.5 microg/ml LTG and 37.8+/-3.2% with 10 microg/ml LTG (p>0.05). In the serum samples from @entity302 mothers, the cord blood maternal concentration ratio was 1.02 in one pair and 1.55 in the other. CONCLUSIONS: LTG crossed the placenta easily and rapidly, indicating that the maternal treatment leads to a considerable foetal exposure.
